Stock Analysis
Relay Therapeutics, Inc. (RLAY) Stock Analysis
Relay Therapeutics, Inc. (RLAY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Relay Therapeutics, Inc. (RLAY) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 76/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RLAY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $18.09 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $3.96B |
| P/E Ratio (TTM) | -11.98 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.37 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.66 |
| Volume | 1.48M |
| 52-week range | $6.04-$21.27 |
| RSI 14 | 47.92 |
| 50-Day SMA | $18.37 |
| 200-Day SMA | $15.54 |
| Analyst Price Target | $29.00 |
| Next Earnings | Feb 25, 2027 |
RLAYRelay Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum76
- Value37
- Quality47
- Risk resilience52
- Sentiment—
RLAY Stock Analysis Summary
Relay Therapeutics, Inc. (RLAY) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 76/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RLAY has AIQ Score of 56/100 with Momentum base of 76/100 and fading Value at 37/100. Wait for component alignment before adding exposure.
Momentum (76/100) leads while Value (37/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.06% stock move · RLAY classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RLAY Bullish or Bearish Right Now?
RLAY currently has a neutral overall setup. Momentum is the strongest factor at 76/100, while Value is weakest at 37/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 76/100.
- - Analyst target implies +60.31% upside from the latest quote.
- - Value is the current constraint at 37/100.
- - Technical consensus has more sell votes than buy votes (25 vs 12).
Current Consensus
RLAY's Technical Analysis Consensus is currently Sell, with 12 buy, 9 neutral, and 25 sell votes. RLAY's 14-day RSI is 47.92, which places the stock in a neutral momentum range. RLAY's beta is 1.66, indicating greater market sensitivity than the broad market.
What Changed in RLAY?
The largest recent change in RLAY is Value moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the RLAY Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RLAY Decision Framework
Public evidence layers, setup checks, and risk context for Relay Therapeutics, Inc..
Relay Therapeutics, Inc. (RLAY) Stock Analysis
Relay Therapeutics, Inc. has an AIQ Score of 56/100 in a Neutral regime. Momentum is strongest at 76/100. Beta is 1.66, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RLAY is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that momentum leads at 76/100 while value lags at 37/100. |
| Factor Evidence | Momentum 76/100 · Value 37/100 · Quality 47/100 · Risk 52/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 76/100.
Momentum is 76/100 and RSI (14) is 47.9.
RLAY is in a Neutral regime at 56/100.
Risk factor is 52/100 with beta 1.66 and annual volatility 65.8%.
Current conflict: momentum leads at 76/100 while value lags at 37/100.
RLAY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RLAY Fundamentals
RLAY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RLAY Technical Analysis
RLAY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RLAY Stock Catalysts
Track RLAY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RLAY Dividend Analysis
RLAY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RLAY Financial Data
RLAY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RLAY Risk Analysis
RLAY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RLAY Stock News
RLAY stock news, market tone, recent headlines, and catalyst context.
RLAY vs Biotechnology Peers
Current peer cohort: RLAY · RVMD · RYTM · SEPN · SLS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RLAY Current stock | 56/100 | 37/100 | 76/100 | 52/100 | 1.84 | 65.80% | Current |
| RVMD Revolution Medicines, Inc. | 55/100 | 39/100 | 73/100 | 59/100 | 1.69 | 68.69% | RLAY vs RVMD |
| RYTM Rhythm Pharmaceuticals, Inc. | 62/100 | 52/100 | 72/100 | 57/100 | 0.52 | 54.57% | RLAY vs RYTM |
| SEPN Septerna Inc | 69/100 | 55/100 | 87/100 | 52/100 | 1.43 | 69.35% | RLAY vs SEPN |
| SLS SELLAS Life Sciences Group, Inc. | 57/100 | — | 55/100 | 32/100 | 2.04 | 109.89% | RLAY vs SLS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for RLAY: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RLAY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RLAY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RLAY Stock FAQ
What is RLAY stock price today?
Relay Therapeutics, Inc.'s current stock price is $18.09. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RLAY bullish or bearish right now?
RLAY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RLAY's market cap?
RLAY's market cap is $3.96B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RLAY's current P/E ratio?
RLAY's current P/E ratio is -11.98 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RLAY's RSI?
RLAY's 14-day RSI is 47.92 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RLAY above its 50-day and 200-day moving averages?
RLAY is -1.54% from its 50-day SMA and 16.43% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RLAY's next earnings date?
RLAY's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RLAY pay a dividend?
RLAY's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.